Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel): A summary of real-world evidence.

被引：0
|
作者：
Yang, Hongbo
Qi, Cynthia Zhengyun
Dalal, Anand
Bollu, Vamsi
Zhang, Jie
Zhang, Su
Lim, Stephen
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19551
引用
收藏
页数：3
相关论文
共 50 条
  • [41] The Phase 3, Randomized Study of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7
    Schmitz, N.
    Oluwole, O. O.
    Bishop, M. R.
    Gisselbrecht, C.
    Gordon, L. I.
    Kersten, M. J.
    Maloney, D. G.
    Caballero, M. D.
    Kuruvilla, J.
    Song, K. W.
    Jacobson, C. A.
    Nastoupil, L. J.
    Riedell, P.
    Jiang, Y.
    Rossi, J. M.
    Lee, L.
    Cheng, P.
    Locke, F. L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 90 - 91
  • [42] Axicabtagene Ciloleucel (Axi-Cel) versus standard-of-care therapy in patients with relapsed/refractory diffuse large B cell lymphoma: The phase 3, randomized study, ZUMA-7
    Schmitz, N.
    Oluwole, O. O.
    Bishop, M. R.
    Gisselbrecht, C.
    Gordon, L. I.
    Kersten, M. J.
    Maloney, D. G.
    Caballero, M. D.
    Kuruvilla, J.
    Song, K. W.
    Jacobson, C. A.
    Nastoupil, L. J.
    Riedell, P.
    Jiang, Y.
    Rossi, J. M.
    Lee, L.
    Cheng, P.
    Locke, F. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 47 - 47
  • [43] Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study
    Oluwole, Olalekan O.
    Bishop, Michael R.
    Gisselbrecht, Christian
    Gordon, Leo I.
    Kersten, Marie Jose
    Maloney, David G.
    Schmitz, Norbert
    Dolores Caballero, Maria
    Kuruvilla, John
    Song, Kevin W.
    Jacobson, Caron A.
    Nastoupil, Loretta J.
    Riedell, Peter
    Jiang, Yizhou
    Rossi, John M.
    Lee, Lillian
    Cheng, Paul
    Locke, Frederick L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S293 - S294
  • [44] Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status
    Saverno, Kim
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Amoloja, Theresa
    Epperla, Narendranath
    Nastoupil, Loretta J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S464 - S464
  • [45] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
  • [46] Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)
    Jacobson, Caron A.
    Westin, Jason R.
    Miklos, David B.
    Herrera, Alex F.
    Lee, Jennifer
    Seng, Judy
    Rossi, John M.
    Sun, Jennifer
    Dong, Jinghui
    Roberts, Zachary J.
    Vezan, Remus
    Avanzi, Mauro P.
    Locke, Frederick L.
    CANCER RESEARCH, 2020, 80 (16)
  • [47] Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Chaganti, Sridhar
    Cwynarski, Kate
    Cunningham, David
    Locke, Frederick L.
    Miklos, David B.
    Jacobson, Caron A.
    Perales, Miguel-Angel
    Kersten, Marie Jose
    Oluwole, Olalekan O.
    Ghobadi, Armin
    Rapoport, Aaron P.
    McGuirk, Joseph P.
    Pagel, John M.
    Munoz, Javier
    Farooq, Umar
    van Meerten, Tom
    Reagan, Patrick M.
    Sureda, Anna
    Flinn, Ian W.
    Vandenberghe, Peter
    Song, Kevin W.
    Dickinson, Michael
    Minnema, Monique C.
    Riedell, Peter A.
    Leslie, Lori A.
    Yang, Yin
    Filosto, Simone
    Schupp, Marco
    To, Christina
    Cheng, Paul
    Gordon, Leo I.
    Radford, John
    Westin, Jason R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 20 - 22
  • [48] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
    Abramson, Jeremy S.
    Kamdar, Manali
    Liu, Fei Fei
    Crotta, Alessandro
    Previtali, Alessandro
    Klijn, Sven L.
    Wang, Pearl
    Situ, Aaron
    Zhang, Yixie
    Bonner, Ashley
    Lunning, Matthew A.
    BLOOD, 2022, 140 : 4655 - 4656
  • [49] ZUMA-7: RANDOMIZED PHASE 3 ESSAY OF AXICABTAGEN CILOLEUCEL (AXI-CEL) VS STANDARD TREATMENT (SOC) IN PATIENTS WITH LYMPHOMA B DIFFUSE OF LARGE CELLS IN RECYCLED/REFRACTORY (R/R DLBCL)
    Caballero, M. D.
    Cwynarski, K.
    Dreger, P.
    Thieblemont, C.
    Vandenberghe, P.
    Zinzani, P. L.
    Mueller, A.
    Greinix, H.
    Avivi, I
    Enblad, G.
    Locke, F. L.
    Yang, Y.
    Brock, K.
    Cheng, P.
    Kersten, M. J.
    HAEMATOLOGICA, 2018, 103 : 359 - 359
  • [50] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
    Oluwole, Olalekan O.
    Forcade, Edouard
    Muñoz, Javier
    de Guibert, Sophie
    Vose, Julie M.
    Bartlett, Nancy L.
    Lin, Yi
    Deol, Abhinav
    McSweeney, Peter A.
    Goy, Andre H.
    Kersten, Marie Jose
    Jacobson, Caron
    Farooq, Umar
    Minnema, Monique C.
    Thieblemont, Catherine
    Timmerman, John M.
    Stiff, Patrick
    Avivi, Irit
    Tzachanis, Dimitrios
    Kim, Jenny J.
    Zheng, Yan
    Shen, Rhine R.
    Vardhanabhuti, Saran
    Van Meerten, Tom
    BLOOD, 2021, 138
12345